Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read MoreYOU MAY HAVE MISSED
